跳至主要内容
临床试验/NCT00098878
NCT00098878已完成3 期

SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers

NHS Greater Glasgow and Clyde176 个研究点 分布在 3 个国家目标入组 1,300 人开始时间: 2004年3月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
1,300
试验地点
176
主要终点
Progression-free survival

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This randomized phase III trial is comparing different doses of carboplatin to see how well they work in treating patients with stage IC, stage II, stage III, or stage IV ovarian, fallopian tube, or primary peritoneal cancer.

详细描述

OBJECTIVES:

Primary

  • Compare progression-free survival of patients with stage IC-IV ovarian epithelial, fallopian tube, or primary peritoneal cancer treated with flat-dose vs intra-patient dose-escalated carboplatin as first-line chemotherapy.

Secondary

  • Compare the toxic effects of these regimens in these patients.
  • Compare the quality of life of patients treated with these regimens.
  • Compare overall clinical response rate and CA 125 response in patients treated with these regimens.
  • Compare overall survival of patients treated with these regimens.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Progression-free survival

次要结局

  • Toxicity
  • Quality of life
  • Clinical overall response rate and CA125 response
  • Overall survival

研究者

申办方类型
Other

研究点 (176)

Loading locations...

相似试验